SCHEMBL3665665

SCHEMBL3665665

COc1cc(-c2cncc(-c3cc(CN)nc(-c4ccccn4)c3)c2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.42
LOX P28300 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
ATR Q13535 1/20 0.37
SYK P43405 1/20 0.37
FFAR1 O14842 1/20 0.36
TGFBR1 P36897 2/20 0.35
MAPT P10636 1/20 0.35
WNT3A P56704 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
GAA P10253 1/20 0.35
SQOR Q9Y6N5 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
GRM5 P41594 2/20 0.34
FAAH O00519 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666895 0.86 NPC1 (0.47) CYP19A1SYKFFAR1TGFBR1MAPT
SCHEMBL3663471 0.86 MEN1 (0.41) SYKFFAR1MAPTGAASQOR
SCHEMBL3662834 0.84 KDM4E (0.41) SYKFFAR1CYP11B1CYP11B2GAA
SCHEMBL3662480 0.82 CYP11B1 (0.43) CYP19A1FFAR1MAPTCYP11B1CYP11B2
SCHEMBL3663615 0.79 CCR1 (0.37) CYP19A1LOXL2PRMT5WDR77GRM5
SCHEMBL3664279 0.78 LOXL2 (0.46) LOXLOXL2ATRPRMT5WDR77
SCHEMBL3664993 0.78 CCR1 (0.34) CYP19A1LOXL2PRMT5WDR77GRM5
SCHEMBL4177155 0.75 HRH1 (0.36) LOXL2FFAR1MAPTGRM5
SCHEMBL8513636 0.73 HSP90AA1 (0.54) FFAR1MAPTGAASQORGRM5
SCHEMBL2238718 0.73 FFAR1 (0.54) CYP19A1FFAR1TGFBR1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK CYP19A1 2071/4885LOX 369/4885LOXL2 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.